Systemic Juvenile Idiopathic Arthritis: Baricitinib Study

We are studying the effectiveness of baricitinib in children aged 1 to under 18 with systemic juvenile idiopathic arthritis. This research aims to find out if it helps improve their condition.

6-12 months Confirmation phase (III)Post-Trial Drug Access Cost Reimbursement Partially Remote Standard Medicines Oral InjectionPediatricsRheumatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Baricitinib

Baricitinib is a substance that reduces immune-driven inflammation to treat rheumatoid arthritis.

Placebo

Placebo is an inactive substance given to mimic a treatment so researchers can measure effects caused by patients' expectations.

Ruxolitinib

Ruxolitinib is a substance that blocks cell signals to reduce abnormal blood cell growth and inflammation in certain bone marrow disorders.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Allgemeines Krankenhaus Der Stadt Wien Universitatskliniken

Universitätsklinik für Kinder- und Jugendheilkunde

Vienna, Austria

UZ Leuven

Kinderreumatologie

Heverlee, Belgium

Universitair Ziekenhuis Gent

Pediatric rheumatology

Ledeberg, Belgium

Sponsor: Eli Lilly & Co.

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.